We are registered as an independent intermediary for medicines with the Dutch Ministry of Health
How to buy Rubraca:
You can order Rubraca (rucaparib) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.
Clovis Oncology Inc.
Deleterious BRCA mutation associated with advanced ovarian cancer
Mode of Action
FDA approved (USA)
300 mg, 200 mg
Who is rucaparib for?
Rubraca (rucaparib) is indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer, who have been treated with two or more chemotherapies . Patients should be selected for therapy based on the FDA-approved FoundationFocus CDxBRCA test (Foundation Medicine Inc.) .
Complete information about Rubraca (rucaparib) dosage and administration can be found here . The standard dosage is:
600 mg orally twice daily.
Patients should be monitored for hematologic toxicity at baseline and monthly thereafter, and use of Rubraca (rucaparib) should be discontinued if myelodysplastic syndrome (MDS) / acute myeloid leukemia (AML) is confirmed . Consult your treating doctor for personalised dosing.
What is rucaparib and how does it work?
Rubraca (rucaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies .Approximately 15 to 20 % of patients with ovarian cancer have a BRCA gene mutation. BRCA genes are involved with repairing damaged DNA and normally work to prevent tumour development. However, mutations of these genes may lead to certain cancers, including ovarian cancers. Rubraca (rucaparib) is a poly ADP-ribose polymerase (PARP) inhibitor that blocks an enzyme involved in repairing damaged DNA. By blocking this enzyme, DNA inside the cancerous cells with damaged BRCA genes may be less likely to be repaired, leading to cell death and possibly a slowdown or stoppage of tumour growth .
What is rucaparib's approval status?
Rubraca (rucaparib) was approved by:
FDA (USA) on December 19, 2016
for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies . The approvals were based on a study involving 106 adults with BRCA-mutated advanced ovarian cancer who had been treated with two or more chemotherapy regimens. BRCA gene mutations were confirmed in 96 % of tested trial participants with available tumour tissue using the FDA approved diagnostic FoundationFocus CDxBRCA . Of the participants who received Rubraca (rucaparib) in the trials, 54 % experienced complete or partial shrinkage of their tumours lasting a median of 9.2 months . The safety of Rubraca (rucaparib) was evaluated in 377 patients with advanced ovarian cancer. The most common adverse reactions (greater than or equal to 20 %) experienced by patients were nausea, fatigue, vomiting, anemia, abdominal pain, dysgeusia, constipation, decreased appetite, diarrhea, thrombocytopenia, and dyspnea. MSD/AML was reported in 2 out of 377 (0.5 %) patients with ovarian cancer. In addition, AML was reported in 2 (<1 %) patients with ovarian cancer enrolled in a blinded, randomised trial evaluating rucaparib versus placebo . On October 12, 2012, the European EMA granted orphan designation to Clovis Oncology UK Limited, United Kingdom, for rucaparib for the treatment of ovarian cancer .
Buyer There is a 6% tax on medicines + 21% tax on shipping for EU individuals
Shipping Cost Estimate
*Once you provide us with the exact shipping address, the actual price may vary.
Send this price estimate to your email address
Ordering with TheSocialMedwork is a safe and legal way to import a prescription medicine that has been approved in another country, but is not yet available where you live.
If you think that this medicine may be suitable for treating your condition, get in touch.
We'll answer any questions you might have and provide you with further information. Select the
tab to get a close estimate of the full cost of the medicine including delivery.
If you would like us to provide you with a precise quote we'll need to know the exact address of where you want us to send your medicine to.
2. Chat with your doctor
About whether this treatment might be suitable for you. In order to place an order with us, you’ll need to provide us with a prescription from your doctor who must be based in the same country where the medicine will be shipped to.
3. Place your order
Once you have your doctor's prescription you’re ready to place an order with us. Payment can be made by credit card, electronic bank transfer or Paypal.
As soon as we receive your payment we’ll process your order and your medicine will be shipped to you via a pharmacy.
Delivery time can vary from country to country but usually takes 1 to 3 weeks.
We'll send you a tracking number and keep you up to date on the status of your order.
Rest assured that we'll guide you through the entire process.
We'll let you know exactly what regulations need to be followed and the specific documentation you'll need to import the medicine into your country so that you get your treatment as quickly as possible. Ask us a question
"TheSocialMedwork helped us to get the medicine, which was not accessible for us, in the shortest possible time."
- Haoyu, China.
Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
DISCLAIMER: The Services of TheSocialMedwork do not replace a physician-patient relationship and are not intended as medical advice. TheSocialMedwork provides patients and physicians with existing treatment options abroad and creates access to these options after the patient and physician have made a professional decision.
Terms and Conditions